I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

AACR 2024

Coming soon
11:30 PM
Duration 29mins California
IMvoke010: A phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)
Deborah J. Wong, Jérôme Fayette, Maria Teixeira, Prabhash Kumar, Ricard Mesia, Andrzej Kawecki, Arunee Dechaphunkul, José Dinis, Ye Guo, Muneyuki Masuda, Ching-Yun Hsieh, Maria Grazia Ghi, Claudia Vaz de Melo Sette, Tao Jiang, Yibing Yan, Monika Kaul, Ritika Jagtiani, Christina Matheny, Vaikunth Cuchelkar, Robert Haddad
08:30 PM
Duration 149mins California, USA
Trastuzumab emtansine in patients (pts) with HER2 mutation-positive (HER2mut) tumors: TAPISTRY study
Kim J-E, Thomas D, Gadgeel S, Corassa M, Tran T, Girda E, Richards D, Tejpar S, Chen D, Fang J, Patel S, Wilson T, Barlesi F
04:00 PM
Duration 210mins California, USA
Tumor Microenvironment (TME) biomarkers of TIGIT and PD-L1 immune checkpoint blockade in Cervical Cancer: An Exploratory Biomarker Analysis from SKYSCRAPER-04 (SKY04) Study
Krishnan V, Chang CW, Bader E, Salani R, Monk BJ, Kim YM, Ghamande S, Hall SL, Lorusso D, Barraclough L, Gilbert L, Ramirez AG, Lu CH, Berton D, Colombo N, Castro M, Lin YG, McCormack M, Molinero L
Duration 210mins California, USA
IMpower010: updated results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC
Wang J, Altorki N, Felip E, Wakelee H, Vallieres, E, Zhou C, Fang J, Min T, He J, Liu Y, Fan Y, Belleli R, McNally V, Bennett E, Gitlitz BJ
Duration 210mins California, USA
RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 China study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC
Caicun Zhou, Charlie Sun, Stacey Huang, Xiaorong Dong, Gongyan Chen, Zhehai Wang, Xianghua Wu, Yu Yao, Yiping Zhang, Ying Cheng, Hongming Pan, Xiaodong Zhang, Jiuwei Cui, Lifeng Wang, Xi Chen, Xiaoling Li, Ziping Wang, Qiming Wang, Jianxing He, Mengzhao Wang, Grace Qian, Qiong Wu, Shanshan Li, Habib Hamidi, David S. Shames, Marcus Ballinger, Minu Srivastava
Duration 210mins California, USA
Phase Ib/II, open-label, randomized evaluation of atezolizumab and etrumadent in combination with chemotherapy in MORPHEUS-pancreatic ductal adenocarcinoma
KP Kim, J Lacy, D-Y Oh, M P Sarvisé, T Macarulla, A Alistar, E O’Reilly, J Lau, T Xu , F Young , H Prizant